SYS6010 is an antibody-drug conjugate targeting epidermal growth factor receptor (EGFR). We report the results of a phase 1 trial (ChiCTR2300072141) of SYS6010 in patients with non-small cell lung cancer (NSCLC). A total of 236 patients were treated. One dose-limiting toxicity occurred at 6.4 mg/kg; therefore, 4.2, 4.5, and 4.8 mg/kg were selected for cohort expansion. Treatment-related adverse events (TRAEs; any/grade ≥ 3) occurred in 99.6%/57.2% of patients. Common grade ≥3 TRAEs included neutropenia (30.9%), leukopenia (25.0%), and thrombocytopenia (17.4%). Objective response rate was 34.7% in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs) and platinum chemotherapy, 45.7% in EGFR-mutant NSCLC treated with EGFR TKIs, 20.0% in EGFR wild-type squamous NSCLC, and 35.7% in EGFR wild-type non-squamous NSCLC. Median progression-free survival and overall survival were 7.6 and 19.4 months, respectively, in EGFR-mutant NSCLC treated with EGFR TKIs and platinum chemotherapy. Overall, SYS6010 shows a manageable safety profile and encouraging antitumor activity in previously treated, advanced NSCLC.
Zi-Ming Li, Zhen Zhou, Zhi-Yong He et al.· Cancer Cell· 0 citations
Oncolytic viral therapy has broad antitumor and immuno-oncology effects that may be useful in managing malignancies, particularly in relapsed or refractory diseases following conventional therapeutic regimens. We report a case involving a patient enrolled in an ongoing phase Ib clinical trial of Olvi-Vec, a modified oncolytic vaccinia virus, in patients with platinum-relapsed/refractory advanced small cell lung cancer (SCLC). In this 58-year-old woman who had progressed after frontline treatment with platinum and etoposide, a deep and durable partial objective response (84.6% reduction in target lesion size) and progression-free survival (16.7 months) were observed following a single course of Olvi-Vec followed by re-challenge with platinum-based therapy. These findings exceed expected clinical outcomes based on historical data. Olvi-Vec therapy was well tolerated. The clinical effect observed in this patient may be related to Olvi-Vec-mediated changes in the tumor microenvironment, potentially leading to platinum re-sensitization. The results of this case report indicate that the role of Olvi-Vec as an oncolytic immunotherapy for cancer treatment warrants additional study.
Yun Chen, Zhiquan Qin, Zi-Ming Li et al.· Frontiers in Oncology· 0 citations
The BAG3+ CAF-T Cell Neighborhood may serve as a biomarker for predicting non-response to NCIT in NSCLC, with significant potential to inform clinical decision-making.
Jing Sun, Zhengqi Cao, Yueping Jin et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
